GMED: Globus Medical, Inc. Stock

by  •  • Comments Off on GMED: Globus Medical, Inc. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 6,940.54
Enterprise Value ($M) 6,890.65
Book Value ($M) 3,997.96
Book Value / Share 29.53
Price / Book 1.74
NCAV ($M) 827.25
NCAV / Share 6.11
Price / NCAV 8.39

Profitability (mra)
Return on Invested Capital (ROIC) 0.03
Return on Assets (ROA) 0.06
Return on Equity (ROE) 0.06

Liquidity (mrq)
Quick Ratio 2.72
Current Ratio 4.88

Balance Sheet (mrq) ($M)
Current Assets 1,915.37
Assets 5,086.08
Liabilities 1,088.12
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1,568.48
Operating Income 273.51
Net Income 122.87
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 243.50
Cash from Investing 302.97
Cash from Financing -231.82

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Paul David C 16.24 -1.53
02-13 13G/A Janus Henderson Group Plc 5.70 40.38
02-13 13G/A Vanguard Group Inc 9.54 -0.05
02-13 13G/A Kayne Anderson Rudnick Investment Management Llc 0.00 -100.00
01-24 13G/A BlackRock Inc. 9.40 14.66

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023  TRANSITION REPORT PURSUANT TO SECTI
2023-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023  TRANSITION REPORT PURSUANT
2023-08-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023  TRANSITION REPORT PURSUANT TO S
2023-05-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023  TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-24 157,008 664,872 23.61
2024-04-23 114,766 900,470 12.75
2024-04-22 124,492 967,602 12.87

(click for more detail)

Similar Companies
EW – Edwards Lifesciences Corporation FNA – Paragon 28, Inc.
GKOS – Glaukos Corporation HAE – Haemonetics Corporation
INSP – Inspire Medical Systems, Inc.


Financial data and stock pages provided by
Fintel.io